Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Approved to Start Trials of Novel I-O and Osteoporosis Candidates

publication date: Jul 26, 2018

Innovent Biologics (Suzhou) received CFDA approval to begin China clinical trials of two novel targeted antibody drugs: IBI101, an anti-OX40 agonistic antibody, and IBI307, an anti-RANKL antibody. Innovent said OX40 is one of the most important targets in immuno-oncology, and the company's molecule is the first OX4 candidate granted China IND approval. The other candidate, IBI307, is aimed at osteoporosis and lytic bone lesions associated with cancer metastasis. There are no RANKL inhibitors approved for China use. Innovent is currently developing seventeen antibody drug candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital